Viatris price target raised to $20 from $18 at Truist
Truist raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. The company’s Q1 results featuring a 5% revenue beat
Fiscal Year: January - December
Viatris Inc. (VTRS), listed on the NASDAQ, has a market capitalization of $20.00B. As of May 09, 2026, the stock is trading at $17.17 per share@else an unavailable price , offering investors a clear view of its current market value. Viatris Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Viatris Inc. also offers a dividend yield of 2.8%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Viatris Inc. (VTRS) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Viatris Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Viatris Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Viatris Inc. is 11.15, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Viatris Inc. (VTRS) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Viatris Inc. (VTRS) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Viatris Inc. (VTRS) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Viatris Inc.. To access the full SS Score, consider upgrading your subscription.
Viatris Inc. is a significant player in the industry sector, with a market capitalization of $20.00B and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Viatris Inc. is outperforming or underperforming within its sector.
Truist raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. The company’s Q1 results featuring a 5% revenue beat
JPMorgan raised the firm’s price target on Viatris (VTRS) to $18 from $17 and keeps a Neutral rating on the shares.
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Confer...
Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, buoyed by strength in its China business and strong demand for branded drugs.
Reports Q1 revenue $3.52B, consensus $3.36B. “We delivered a strong first quarter, reflecting disciplined execution across our global businesses,” said Scott A. Smith, CEO, Viatris (VTRS). “Our perfor...
Backs FY26 revenue view $14.45B-$14.95B, consensus $14.64B. Backs FY26 adjusted EBITDA view $4.15B-$4.45B.
Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to ...
PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and out...
Viatris (VTRS) announced that Theodora “Doretta” Mistras, CFO, will depart the company for a new professional opportunity. Viatris has named Paul Campbell, currently Chief Accounting Officer and Corpo...
Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "D...
PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contrace...
PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Compa...
PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refra...
Barclays raised the firm’s price target on Viatris (VTRS) to $17 from $15 and keeps an Overweight rating on the shares. The “muted reaction” to Viatris’ investor day is unsurprising
Viatris (VTRS) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has approved Effexor SR 37.5 mg / 75 mg capsules, a serotonin-noradrenaline reuptake inhibitor, for the treatment
Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, tod...
Viatris (VTRS) will host its Investor Event, where members of the executive leadership team will outline the Company’s strategic vision, key drivers and financial framework expected to deliver sustain...
Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxic...
Generic drugmaker Viatris has settled a lawsuit brought by the family of Henrietta Lacks, a Maryland woman whose tissue samples were used without her permission to develop enduring cells for lucrativ...
Unusual total active option classes on open include: Grabagun Digital Holdings Inc. (PEW), Viatris (VTRS), SK Telecom (SKM), Dicks (DKS), Mosaic (MOS), Poet Technologies (POET), United States Brent Oi...
It can seem like a nothing-to-buy market. But there are solid stocks out there.
UBS raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. Viatris achieved its Q4 cost-saving targets and provided FY26
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 1.76B | Analyst x2 | |
| 2027 | 1.99B | 13.33% | Analyst x2 |
| 2028 | 2.27B | 14.14% | Analyst x1 |
| 2029 | 2.46B | 8.27% | Analyst x1 |
| 2030 | 2.57B | 4.63% | Est @4.6% |
| 2031 | 2.68B | 4.04% | Est @4.0% |
| 2032 | 2.78B | 3.62% | Est @3.6% |
| 2033 | 2.87B | 3.34% | Est @3.3% |
| 2034 | 2.95B | 2.92% | Est @2.9% |
| 2035 | 3.03B | 2.79% | Est @2.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 1.98B | 1.00 | 1.98B |
| 2025A | 1.94B | 1.00 | 1.94B |
| 2026E | 1.76B | 1.08 | 1.63B |
| 2027E | 1.99B | 1.17 | 1.71B |
| 2028E | 2.27B | 1.26 | 1.80B |
| 2029E | 2.46B | 1.36 | 1.81B |
| 2030E | 2.57B | 1.47 | 1.75B |
| 2031E | 2.68B | 1.58 | 1.69B |
| 2032E | 2.78B | 1.71 | 1.62B |
| 2033E | 2.87B | 1.85 | 1.55B |
| 2034E | 2.95B | 1.99 | 1.48B |
| 2035E | 3.03B | 2.15 | 1.41B |
| Terminal | 56.79B | 2.15 | 26.37B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.